- Global Pharma News & Resources

UK Post EBMT Update Day: New data presented on haematopoietic stem cell transplantation using Treosulfan- based conditioning regimen

FOR MEDICAL AND CONSUMER MEDIA   Stirling, UK   Following the Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) last month, the UK Post EBMT update meeting was held virtually last week where Dr Daniele Avenoso from Kings College Hospital, London presented data highlights from medac’s EBMT symposium, “Current Developments in Allogeneic Haematopoietic Stem Cell Transplantation: Recent Data on Treosulfan (Trecondi®).” The meeting was attended by over 100 delegates from UK hospitals and the presentation generated questions from attendees around preferred conditioning regimens and products. Dr Daniele Avenoso presented data from Consultant Haematologists Professor Arnon Nagler (Israel) and Dr Friedrich Stölzel (Germany) which showed that a treosulfan reduced intensity conditioning regimen offers a new bone marrow transplant option for patients affected by neoplastic diseases. Further to this, the data showed that treosulfan based conditioning is not inferior to other conditioning regimens (all donor types) and may have better efficacy in patients with active disease.


The reduced toxicity of the new treosulfan/fludarabine-based regimen makes myeloablative conditioning an option for a broad range of adults and children that were not suitable for this treatment before now (AML and MDS, as well as for additional malignant and non-malignant diseases).The clinical outcome shown in this presentation highlights that the treosulfan conditioning regimen in combination with fludarabine has the potential to become the new standard regimen for conditioning prior to allogeneic HSCT.


About medac Pharma

medac Pharma is part of medac GmbH, a privately held, multi-national pharmaceutical company with a growing pharmaceutical and diagnostics business. Founded in Germany in 1970, medac specialises in the treatment of diseases within the fields of oncology, haematology, autoimmune and urology by providing both basic and speciality therapeutics. The company has offices globally, worldwide partner agreements in over 90 countries and approximately 1,200 employees. Trecondi® in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases1. It is the only conditioning regimen to be NICE recommended2.
  1. Product SPC - Trecondi
  2. NICE guidelines - Trecondi
  Press contact:
Lauren Addison
Phone: 07557 023607

Editor Details

Last Updated: 28-Apr-2021